Barclays Downgrades Coloplast A/S (OTCMKTS:CLPBY) to Hold

Barclays cut shares of Coloplast A/S (OTCMKTS:CLPBY) from a strong-buy rating to a hold rating in a research report report published on Wednesday morning,Zacks.com reports.

CLPBY has been the topic of a number of other reports. Sanford C. Bernstein raised shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 28th. Royal Bank of Canada upgraded Coloplast A/S from a “hold” rating to a “moderate buy” rating in a report on Monday, March 3rd. Three analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Coloplast A/S Stock Down 2.9 %

OTCMKTS CLPBY opened at $9.61 on Wednesday. The business has a fifty day moving average price of $10.56 and a 200 day moving average price of $11.35. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.02 and a quick ratio of 0.66. Coloplast A/S has a one year low of $9.61 and a one year high of $14.14.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Coloplast A/S had a net margin of 17.81% and a return on equity of 28.60%. On average, equities research analysts forecast that Coloplast A/S will post 0.31 EPS for the current fiscal year.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.